PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM

Rang in Aktien #39391
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Aktienkurs
$0.11725176
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$481.50K
Veränderung (1 Tag)
-0.20%
Veränderung (1 Jahr)
-1.64%
Land
FR
Handel PHAXIAM Therapeutics S.A. (PHXM)

Kategorie

Healthcare
Aktien-Split-Historie für PHAXIAM Therapeutics S.A. (PHXM)
Die Aktie PHAXIAM Therapeutics S.A. (Symbol: PHXM) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Oct 21, 2026 statt.
Eine PHXM-Aktie, die vor dem Oct 21, 2026 gekauft wurde, entspricht heute 0 PHXM-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL